MedPath

A randomized phase II study of Pemetrexed plus Carboplatin followed by Pemetrexed versus Paclitaxel plus Carboplatin followed by Pemetrexed in patients with chemotherapy naïve non-squamous non-small cell lung cancer.

Phase 2
Conditions
Chemotherapy na&amp
iuml
ve non-squamous non-small cell lung cancer
Registration Number
JPRN-UMIN000005008
Lead Sponsor
ung Oncology Group in Kyushu, Japan (LOGIK)
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up continuing
Sex
All
Target Recruitment
140
Inclusion Criteria

Not provided

Exclusion Criteria

Severe complicaiton including heart disease, pulmonary fibrosis, bleeding tendency, uncontrollable hypertension and diabetes mellitus. Patients with symptomatic brain metastasis. Active concomitant malignancy. Past history of drug hypersensitivity. Psychiatric disorder. Systemic steroid administration.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Progression Free Survival
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath